NRIX Covered Call Strategy
NRIX (Nurix Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
NRIX (Nurix Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.98B, a beta of 1.87 versus the broader market, a 52-week range of 8.195-23.715, average daily share volume of 1.9M, a public-listing history dating back to 2020, approximately 314 full-time employees. These structural characteristics shape how NRIX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.87 indicates NRIX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a covered call on NRIX?
A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.
Current NRIX snapshot
As of June 30, 2026, spot at $24.15, ATM IV 112.00%, IV rank 15.70%, expected move 32.11%. The covered call on NRIX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this covered call structure on NRIX specifically: NRIX IV at 112.00% is on the cheap side of its 1-year range, which means a premium-selling NRIX covered call collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 32.11% (roughly $7.75 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NRIX expiries trade a higher absolute premium for lower per-day decay. Position sizing on NRIX should anchor to the underlying notional of $24.15 per share and to the trader's directional view on NRIX stock.
NRIX covered call setup
The NRIX covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NRIX near $24.15, the first option leg uses a $25.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NRIX chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NRIX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $24.15 | long |
| Sell 1 | Call | $25.00 | $1.48 |
NRIX covered call risk and reward
- Net Premium / Debit
- -$2,267.50
- Max Profit (per contract)
- $232.50
- Max Loss (per contract)
- -$2,266.50
- Breakeven(s)
- $22.68
- Risk / Reward Ratio
- 0.103
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.
NRIX covered call payoff curve
Modeled P&L at expiration across a range of underlying prices for the covered call on NRIX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$2,266.50 |
| $5.35 | -77.9% | -$1,732.64 |
| $10.69 | -55.7% | -$1,198.78 |
| $16.03 | -33.6% | -$664.92 |
| $21.36 | -11.5% | -$131.06 |
| $26.70 | +10.6% | +$232.50 |
| $32.04 | +32.7% | +$232.50 |
| $37.38 | +54.8% | +$232.50 |
| $42.72 | +76.9% | +$232.50 |
| $48.06 | +99.0% | +$232.50 |
When traders use covered call on NRIX
Covered calls on NRIX are an income strategy run on existing NRIX stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
NRIX thesis for this covered call
The market-implied 1-standard-deviation range for NRIX extends from approximately $16.40 on the downside to $31.90 on the upside. A NRIX covered call collects premium on an existing long NRIX position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether NRIX will breach that level within the expiration window. Current NRIX IV rank near 15.70% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on NRIX at 112.00%. As a Healthcare name, NRIX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NRIX-specific events.
NRIX covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NRIX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NRIX alongside the broader basket even when NRIX-specific fundamentals are unchanged. Short-premium structures like a covered call on NRIX carry tail risk when realized volatility exceeds the implied move; review historical NRIX earnings reactions and macro stress periods before sizing. Always rebuild the position from current NRIX chain quotes before placing a trade.
Frequently asked questions
- What is a covered call on NRIX?
- A covered call on NRIX is the covered call strategy applied to NRIX (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With NRIX stock trading near $24.15, the strikes shown on this page are snapped to the nearest listed NRIX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are NRIX covered call max profit and max loss calculated?
- Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the NRIX covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 112.00%), the computed maximum profit is $232.50 per contract and the computed maximum loss is -$2,266.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a NRIX covered call?
- The breakeven for the NRIX covered call priced on this page is roughly $22.68 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NRIX market-implied 1-standard-deviation expected move is approximately 32.11%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a covered call on NRIX?
- Covered calls on NRIX are an income strategy run on existing NRIX stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
- How does current NRIX implied volatility affect this covered call?
- NRIX ATM IV is at 112.00% with IV rank near 15.70%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.